Economic outcomes in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate plus prednisone

Abstract Authors: Krishnan Ramaswamy, Stanislav Lechpammer, Jack Mardekian, Ahong Huang, Neil M Schultz, Rickard Sandin, Li Wang, Onur Baser, Daniel J George Introduction: Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for...